Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPOX | P50336 | 16/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.65 |
| ▸ | PGK1 | P00558 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL39055 | 1.00 | PPOX (0.65) | PPOXMEN1KMT2ATDP1NR1I2 | |
| Acetone SCHEMBL532802 | 0.96 | PPOX (0.61) | PPOXMEN1KMT2ATDP1NR1I2 | |
| Isopropylamine SCHEMBL19641800 | 0.95 | PPOX (0.66) | PPOXMEN1KMT2ATDP1NR1I2 | |
| Oxadiazon SCHEMBL4659772 | 0.93 | PPOX (0.79) | PPOXMEN1KMT2ATDP1NR1I2 | |
| SCHEMBL20425261 | 0.92 | PPOX (0.57) | PPOXMEN1KMT2ATDP1NR1I2 | |
| SCHEMBL14505698 | 0.91 | PPOX (0.57) | PPOXMEN1KMT2ATDP1NR1I2 | |
| SCHEMBL10437860 | 0.90 | PPOX (0.53) | PPOXMEN1KMT2ATDP1NR1I2 | |
| Simazine SCHEMBL7579114 | 0.88 | PPOX (0.52) | PPOXMEN1KMT2ATDP1NR1I2 | |
| Ioxynil SCHEMBL7581894 | 0.88 | PPOX (0.52) | PPOXMEN1KMT2ATDP1NR1I2 | |
| Clopyralid SCHEMBL7576728 | 0.87 | PPOX (0.52) | PPOXMEN1KMT2ATDP1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008261-A1 | METHOD TO PRODUCE A SUBSTRATE WITH A FOAM LAYER AND SUCH A BUILDING PANEL | Välinge Innovation AB (SE) | 2026-01-08 | — | — | US | disclosed |
| US-11939478-B2 | Metallic inks composition for digital offset lithographic printing | XEROX CORPORATION (US) | 2024-03-26 | — | — | US | disclosed |
| EP-3878913-B1 | METALLIC INKS COMPOSITION FOR DIGITAL OFFSET LITHOGRAPHIC PRINTING | XEROX CORP (US) | 2024-01-31 | — | — | EP | disclosed |
| US-11280772-B2 | Time temperature indicator | FRESHPOINT QUALITY ASSURANCE LTD. (IL) | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008261-A1 | METHOD TO PRODUCE A SUBSTRATE WITH A FOAM LAYER AND SUCH A BUILDING PANEL | FLNB, FLNA, PRPF8 | PPOX 2149/4885MEN1 4135/4885KMT2A 2997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.